Mitsubishi Tanabe Pharma America, Inc. (MTPA) has announced that Mitsubishi Tanabe Pharma Corporation (MTPC), its parent company and a global leader in neurological disease therapeutics, has signed a strategic research collaboration with Dewpoint Therapeutics, Inc.

The collaboration focuses on developing a novel TDP-43 small molecule condensate modulator (c-mod) for amyotrophic lateral sclerosis (ALS), furthering MTPC's commitment to advancing innovation in ALS and central nervous system (CNS) diseases.

Under the terms of the agreement, MTPC will pay Dewpoint an upfront payment. Upon reaching certain pre-specified milestones, MTPC will have the exclusive option to license the program and assume responsibility for global clinical development and commercialization.

"ALS remains one of the most challenging diseases to treat, with limited treatment options for patients. Through this collaboration with Dewpoint Therapeutics, we hope to advance innovative approaches to address this devastating disease by leveraging their expertise in condensate biology. Together, we are committed to making a meaningful difference for patients living with ALS,” said Yasutoshi Kawakami, President, MTPA.

The TDP-43 small molecule condensate modulator is being developed to target key underlying biological mechanisms associated with ALS. TDP-43 is a protein known to play a critical role in ALS pathology, where its dysregulation contributes to neuronal cell death and dysfunction. This innovative approach seeks to address TDP-43's pathological aggregation, with the potential to advance understanding of ALS.

This collaboration reflects MTPC's continued focus on central nervous system diseases, including ALS. With the development of RADICAVA® (edaravone) and RADICAVA ORS® (edaravone), MTPC remains a global leader in advancing ALS care and is committed to addressing the unmet needs of patients and families living with ALS.